DCGI temporarily postpones lab inspections in order to concentrate on cough syrup producers
The problem with subpar cough syrup started when cough syrup from India was purportedly connected to infant fatalities in Uzbekistan and the Gambia.
There were potentially harmful amounts of diethylene glycol and ethylene glycol in the purported Indian cough medication.
To make sure that employees are maintained to "the highest standards," the Drugs Controller General of India (DCGI) has temporarily halted risk-based inspections of industrial facilities and private testing labs across India, sources told CNBC-TV18. must be used for specific, "Priority" verification of cough syrup.
According to sources, DCGI has delayed State/UT inspection in order to make sure that workers are assigned to verify cough syrups on a "top priority" basis first.
According to sources, the risk-based examination of private testing labs and pharmaceutical producers has been put on hold until further notice. A pan-India risk-based examination was scheduled by the agency for December 11–22, 2023.
The DCGI will begin a nationwide risk-based inspection campaign, according to a report from CNBC-TV18 on November 24.
Inspector personnel are required to verify and evaluate the quality of cough syrup, propylene glycol, and importers, according to CNBC-TV18.
Problems with subpar cough syrup were first revealed in October 2022 when 70 children's deaths in the Gambia were connected to cough syrup made by Indian producer Maiden Pharma. Following this, Marion Biotech's cough syrup caused the deaths of 19 individuals in Uzbekistan in only three months.
These problems continued until 2023, so much so that when the World Health Organization (WHO) brought attention to these problems with cough syrups made in India,
Reports from the affected nations said that the cough syrup had harmful amounts of hazardous ingredients, namely ethylene and diethylene glycol.
No comments:
Post a Comment